Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer - PubMed (original) (raw)
Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer
Masakazu Toi et al. Int J Cancer. 2002.
Abstract
Angiogenesis, the formation of new blood vessels, is controlled by a balance between positive and negative endothelial regulatory factors. Soluble vascular endothelial growth factor receptor-1 (sVEGFR1), a naturally occurring soluble form of VEGFR1, is a negative counterpart of the vascular endothelial growth factor (VEGF) signaling pathway, which has been characterized as one of the most important endothelial regulators in human tumor angiogenesis. In our study, we examined the expression of sVEGFR1 in 110 primary breast carcinomas, and assessed its clinical significance. Ninety-four of 110 tumors showed > or = 0.1 ng/mg protein of sVEGFR1 (range:0. 1-6.9 ng/mg protein; median: 1.03 ng/mg protein) as determined by a specific enzyme-linked immunosorbent assay (ELISA). Immunoblot analysis confirmed the presence of sVEGFR1 in breast tumor tissues. The levels of sVEGFR1 were correlated significantly with the levels of VEGF. There was no significant correlation between the levels of sVEGFR1 and any clinico-pathological factors including age, menopause, nodal involvement and hormone receptor status. A univariate prognosis analysis showed that the intratumoral VEGF status, as determined by ELISA, was a significant prognostic indicator, but sVEGFR1 status was not. In the combined analysis, however, the ratio of sVEGFR1 and VEGF levels provided more statistically significant prognostic value than VEGF status alone. Tumors in which the sVEGFR1 levels exceeded VEGF levels 10-fold had a markedly favorable prognosis. Multivariate analysis also demonstrated that the ratio of sVEGFR1 and VEGF was an independent prognostic indicator after nodal status. In conclusion, sVEGFR1, an intrinsic inhibitor of VEGF, frequently co-expressed with VEGF in primary breast cancer tissues. The intratumoral balance between sVEGFR1 and VEGF levels might be crucial for the progression of breast cancer.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
- Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.
Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T. Gasparini G, et al. J Natl Cancer Inst. 1997 Jan 15;89(2):139-47. doi: 10.1093/jnci/89.2.139. J Natl Cancer Inst. 1997. PMID: 8998183 - VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
Fine BA, Valente PT, Feinstein GI, Dey T. Fine BA, et al. Gynecol Oncol. 2000 Jan;76(1):33-9. doi: 10.1006/gyno.1999.5658. Gynecol Oncol. 2000. PMID: 10620438 - Interleukin-4 and granulocyte-macrophage colony-stimulating factor mediates the upregulation of soluble vascular endothelial growth factor receptor-1 in RAW264.7 cells-a process in which p38 mitogen-activated protein kinase signaling has an important role.
Xia L, Dong Z, Zhang Y, Zhang X, Song X, Sun M, Hu Y, Liu S, Wang K, Qu X, Wei F. Xia L, et al. J Microbiol Immunol Infect. 2016 Jun;49(3):344-51. doi: 10.1016/j.jmii.2014.06.008. Epub 2014 Aug 12. J Microbiol Immunol Infect. 2016. PMID: 25132397 - Prognostic value of vascular endothelial growth factor in breast cancer.
Gasparini G. Gasparini G. Oncologist. 2000;5 Suppl 1:37-44. doi: 10.1634/theoncologist.5-suppl_1-37. Oncologist. 2000. PMID: 10804090 Review. - Bronchopulmonary dysplasia: "a vascular hypothesis".
Abman SH. Abman SH. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1755-6. doi: 10.1164/ajrccm.164.10.2109111c. Am J Respir Crit Care Med. 2001. PMID: 11734417 Review. No abstract available.
Cited by
- A Synopsis of Biomarkers in Glioblastoma: Past and Present.
Tataranu LG, Turliuc S, Rizea RE, Dricu A, Alexandru O, Staicu GA, Kamel A. Tataranu LG, et al. Curr Issues Mol Biol. 2024 Jul 3;46(7):6903-6939. doi: 10.3390/cimb46070412. Curr Issues Mol Biol. 2024. PMID: 39057054 Free PMC article. Review. - Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients.
Zarychta E, Bielawski K, Wrzeszcz K, Rhone P, Ruszkowska-Ciastek B. Zarychta E, et al. Int J Mol Sci. 2023 Aug 31;24(17):13508. doi: 10.3390/ijms241713508. Int J Mol Sci. 2023. PMID: 37686312 Free PMC article. - Bioactive VEGF-C from E. coli.
Rauniyar K, Akhondzadeh S, Gąciarz A, Künnapuu J, Jeltsch M. Rauniyar K, et al. Sci Rep. 2022 Oct 28;12(1):18157. doi: 10.1038/s41598-022-22960-0. Sci Rep. 2022. PMID: 36307539 Free PMC article. - In vivo targeting of breast cancer with a vasculature-specific GQDs/hMSN nanoplatform.
Dong J, Yao X, Sun S, Zhong Y, Qian C, Yang D. Dong J, et al. RSC Adv. 2019 Apr 12;9(20):11576-11584. doi: 10.1039/c9ra01833f. eCollection 2019 Apr 9. RSC Adv. 2019. PMID: 35520225 Free PMC article. - New Advances in Targeted Therapy of HER2-Negative Breast Cancer.
An J, Peng C, Xie X, Peng F. An J, et al. Front Oncol. 2022 Mar 4;12:828438. doi: 10.3389/fonc.2022.828438. eCollection 2022. Front Oncol. 2022. PMID: 35311116 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical